Kinase Inhibitors for Anticancer Therapies
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Bioorganic Chemistry".
Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 887
Special Issue Editor
Interests: drug discovery; therapeutic developments for cancer and neurodegenerative disorders; computational molecular modeling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Targeting kinase pathways has emerged as a promising strategy in the fight against debilitating diseases such as cancer that involve aberrant expression of the kinases and infectious diseases caused by pathogenic microbes such as bacteria, viruses, parasites, or fungi. Targeting protein kinases for cancer treatment has emerged as a successful clinical strategy leading to a reduction in the mortality rate for several cancers. The discovery of the roles of additional protein kinase targets and the development of resistance to existing therapeutics has invigorated research for the development of new potential drug candidates as protein kinase inhibitors to combat cancer.
This Special Issue entitled “Kinase Inhibitors for Anticancer Therapies” will showcase the recent trends in the field of drug discovery of kinase inhibitors, especially for anticancer therapy. In addition, review articles, research articles, and short communications will highlight the efforts of medicinal chemists to propose new molecules endowed with kinase inhibition properties and the strategies to enhance the activity profile of the existing pipeline.
Dr. Jayalakshmi Sridhar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- protein kinase inhibitors
- medicinal chemistry
- cancer
- antitumor agents
- small molecules
- drug design
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
